Doina Ganea

Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Inhibition of microglial CD40 expression by pituitary adenylate cyclase-activating polypeptide is mediated by interleukin-10.

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells.

Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor.

VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells.

Galanin down-regulates microglial tumor necrosis factor-alpha production by a post-transcriptional mechanism.

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.

Vasoactive intestinal peptide inhibits IL-8 production in human monocytes.

Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity.

Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.

The neuropeptides VIP/PACAP and T cells: inhibitors or activators?

PACAP in immunity and inflammation.

Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma.

Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells.

Acute down-regulation of antibody production following spinal cord injury: role of systemic catecholamines.

Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells.

VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.

The significance of vasoactive intestinal peptide in immunomodulation.

Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells.

VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.

A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2.

Prostaglandin E2 promotes the survival of bone marrow-derived dendritic cells.

Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.

Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo.

The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells.

Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors.

Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.

Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis.

Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response.

Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease.

Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.

Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation.

Vasoactive intestinal polypeptide induces regulatory dendritic cells that prevent acute graft versus host disease and leukemia relapse after bone marrow transplantation.

Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis.

VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease.

VIP protects Th2 cells by downregulating granzyme B expression.

A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.

The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis.

Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis.

Neuropeptides: active participants in regulation of immune responses in the CNS and periphery.

PGE2-induced metalloproteinase-9 is essential for dendritic cell migration.

A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.

In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells.

Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells.

Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury.

Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.

CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury.

Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation.

Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.

Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family.

IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9.

The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury.

Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.

Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis.

Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation.

Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation.

Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.